Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
ORIGINAL ARTICLES
Anti-HBs-Positive Liver Failure Due to Hepatitis B Virus Reactivation Induced by Rituximab
Toshiki SeraYoichi HiasaKojiro MichitakaIchiro KonishiKana MatsuuraYoshio TokumotoBunzo MatsuuraTakeshi KajiwaraToshikazu MasumotoNorio HoriikeMorikazu Onji
Author information
JOURNALS OPEN ACCESS

2006 Volume 45 Issue 11 Pages 721-724

Details
Abstract

A 59-year-old man developed acute hepatitis with reactivated hepatitis B virus (HBV) following administration of rituximab (anti-CD20 monoclonal antibody). The patient was diagnosed with malignant lymphoma in 1998, and virus marker testing indicated HBV surface antigen (HBsAg)-negative and anti-HBs antibody (anti-HBs)-positive results when chemotherapy including rituximab was started. Levels of aminotransferases were elevated, and HBsAg results turned positive. Despite therapy for late-onset hepatic failure, the patient died. Rituximab appears likely to have induced HBV reactivation in this case. Anti-viral agents should be administered for both HBsAg-positive and anti-HBs-positive patients who are scheduled to receive rituximab.

Information related to the author
© 2006 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top